Suppr超能文献

早期应用机械循环支持稳定并可能挽救难治性心源性休克患者。

Early Escalation of Mechanical Circulatory Support Stabilizes and Potentially Rescues Patients in Refractory Cardiogenic Shock.

机构信息

Departments of Cardiology and Angiology (J.T., J.-T.S., L.C.N., U.F., P.R., J.B., A.S.), Hannover Medical School, Germany.

Cardiothoracic, Transplantation and Vascular Surgery (C.K., J.D.S., A.H.), Hannover Medical School, Germany.

出版信息

Circ Heart Fail. 2020 Mar;13(3):e005853. doi: 10.1161/CIRCHEARTFAILURE.118.005853. Epub 2020 Mar 13.

Abstract

BACKGROUND

Limited progress has been made in the management of cardiogenic shock (CS). Morbidity and mortality of refractory CS remain high. The effects of mechanical circulatory support (MCS) are promising, although many aspects are elusive. We evaluated efficacy and safety of early combined MCS (Impella microaxial pump + venoarterial extracorporeal membrane oxygenation [VA-ECMO]) in refractory CS and aimed to determine factors for decision-making in combined MCS.

METHODS AND RESULTS

We analyzed 69 consecutive patients with refractory CS from our registry requiring combined MCS. In 12 cases, therapy was actively withdrawn according to patient's will. Patients were severely sick (Survival After Venoarterial ECMO score mean±SD, -8.9±4.4) predicting 30% in-hospital survival; ventilation 94%, dialysis 56%. Impella pumps and VA-ECMO were combined early (duration of combined MCS: median 94 hours; interquartile range, 49-150 hours). Early MCS escalation stabilized patients rapidly, reducing number and doses of catecholamines (<0.05 versus baseline) while hemodynamics improved. Reflecting an improved microcirculation, lactate levels normalized within 24 hours (<0.05 versus baseline). Despite refractory CS and disease severity, survival was favorable (on MCS 61%, 30 days 49%, 6 months 40%). In multivariate Cox-regression, duration of shock-to-first device (hours, hazard ratio, 1.05 [95% CI, 1.01-1.08]; =0.007) and lactate levels after 12 hours of MCS (hazard ratio, 1.28 [95% CI, 1.09-1.51]; =0.002) independently predicted survival. Additional right ventricular failure predisposed to futility (hazard ratio, 8.48 [95% CI, 1.85-38.91]; =0.006).

CONCLUSIONS

The early and consequent combination of MCS by Impella microaxial pumps and VA-ECMO enables stabilization and may rescue high-risk patients with refractory CS at low overall risk. Independent predictors of survival may guide prognostication, decision-making, and allocation of medical resources.

摘要

背景

在治疗心源性休克(CS)方面,进展有限。难治性 CS 的发病率和死亡率仍然很高。机械循环支持(MCS)的效果很有前景,但仍有许多方面难以捉摸。我们评估了早期联合 MCS(Impella 微轴流泵+静脉动脉体外膜肺氧合[VA-ECMO])在难治性 CS 中的疗效和安全性,并旨在确定联合 MCS 决策的因素。

方法和结果

我们从我们的登记处分析了 69 例需要联合 MCS 的难治性 CS 连续患者。在 12 例中,根据患者的意愿主动停止治疗。患者病情严重(生存后静脉动脉 ECMO 评分平均值±标准差,-8.9±4.4)预测院内 30%的存活率;通气 94%,透析 56%。Impella 泵和 VA-ECMO 早期联合(联合 MCS 持续时间:中位数 94 小时;四分位距,49-150 小时)。早期 MCS 升级迅速稳定患者,减少儿茶酚胺的用量和剂量(<0.05 与基线相比),同时改善血液动力学。反映微循环改善,乳酸水平在 24 小时内正常化(<0.05 与基线相比)。尽管 CS 难治且病情严重,但生存率良好(在 MCS 上 61%,30 天 49%,6 个月 40%)。在多变量 Cox 回归中,休克至首次使用设备的时间(小时,风险比,1.05[95%置信区间,1.01-1.08];=0.007)和 MCS 后 12 小时的乳酸水平(风险比,1.28[95%置信区间,1.09-1.51];=0.002)独立预测生存率。右心室衰竭增加了无效的可能性(风险比,8.48[95%置信区间,1.85-38.91];=0.006)。

结论

早期连续使用 Impella 微轴流泵和 VA-ECMO 进行 MCS 的联合可以实现稳定,并可能以较低的总体风险挽救高危难治性 CS 患者。生存的独立预测因素可指导预后、决策制定和医疗资源分配。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验